Financials in USD. Standardized financial statements.
A compact view of how Halozyme Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.40B | $1.02B | $829.25M | $660.12M | $443.31M | $267.59M | $195.99M | $151.86M | $316.61M | $146.69M |
| Revenue Growth? | +37.6% | +22.4% | +25.6% | +48.9% | +65.7% | +36.5% | +29.1% | -52.0% | +115.8% | 0.0% |
| Cost of Revenue? | $305.44M | $159.42M | $192.36M | $139.30M | $81.41M | $43.37M | $45.55M | $10.14M | $31.15M | $33.21M |
| Gross Profit? | $1.09B | $855.91M | $636.89M | $520.81M | $361.90M | $224.23M | $150.45M | $141.73M | $285.46M | $113.48M |
| Gross Margin? | +78.1% | +84.3% | +76.8% | +78.9% | +81.6% | +83.8% | +76.8% | +93.3% | +90.2% | +77.4% |
| Operating Expenses? | $274.88M | $304.43M | $299.32M | $253.28M | $86.00M | $79.97M | $218.06M | $211.06M | $204.46M | $196.69M |
| Operating Income? | $816.29M | $551.48M | $337.57M | $267.53M | $275.90M | $144.25M | -$67.61M | -$69.33M | $81.00M | -$83.21M |
| EBITDA? | $904.34M | $656.54M | $451.95M | $315.51M | $259.04M | $152.96M | -$56.56M | -$69.33M | $83.16M | -$79.47M |
| Income Before Tax | $466.88M | $557.13M | $348.33M | $248.92M | $248.52M | $129.30M | -$72.25M | -$79.79M | $61.61M | -$101.86M |
| Income Tax Expense | $149.99M | $113.04M | $66.73M | $46.79M | -$154.19M | $217,000 | -$11,000 | $537,000 | -$1.36M | $1.16M |
| Net Income? | $316.89M | $444.09M | $281.59M | $202.13M | $402.71M | $129.09M | -$72.24M | -$80.33M | $62.97M | -$103.02M |
| EPS? | $2.64 | $3.50 | $2.13 | $1.48 | $2.86 | $0.95 | $-0.50 | $-0.56 | $0.46 | $-0.81 |
| Diluted EPS? | $2.56 | $3.43 | $2.10 | $1.44 | $2.74 | $0.91 | $-0.50 | $-0.56 | $0.45 | $-0.81 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality